Study With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection Fraction

← catalyst calendar

NCT06736574 · readout ≤ 407 d

Sponsored by Cytokinetics (industry) · CYTK — their whole pipeline →.

Phase

Phase 3

Status

Recruiting

Study type

Interventional

Design

Randomized · Quadruple · Treatment

Enrollment

1,800estimated

Sites

201

Countries

Canada, China, France +7

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis

Date

Filed

Basis

What it is

Start

2024-12-19

actual

When the study began enrolling

Primary completion

Sep 2027

estimated

The date the last participant is measured for the primary outcome — the readout window

Study completion

Dec 2027

estimated

The whole study's end, after follow-up

First posted

2024-12-16

actual

When this record first appeared on the registry

Results posted

—

When the sponsor posted results to the registry

Record updated

2026-08-18

actual

The sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Conditions

Heart Failure
Heart Failure With Reduced Ejection Fraction

Interventions

Drug: Omecamtiv Mecarbil (OM)
Drug: Placebo

Primary outcome

what the primary-completion date above is the date OF

Time to the first of event of CV death, HF event, LVAD implantation/cardiac transplantation, or stroke

measured From randomization to the first event of CV death or HF event, whichever occurs first, assessed until the last patient exits the study, estimated to last about 3 years

Publications

PMID 40544170 — linked by the registry

Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.

Permalink · CYTK's whole pipeline · Catalyst calendar · Every registered study · What changed